[go: up one dir, main page]

DE69636934D1 - Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen - Google Patents

Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen

Info

Publication number
DE69636934D1
DE69636934D1 DE69636934T DE69636934T DE69636934D1 DE 69636934 D1 DE69636934 D1 DE 69636934D1 DE 69636934 T DE69636934 T DE 69636934T DE 69636934 T DE69636934 T DE 69636934T DE 69636934 D1 DE69636934 D1 DE 69636934D1
Authority
DE
Germany
Prior art keywords
amino acids
disorders
treatment
movement disorders
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636934T
Other languages
English (en)
Inventor
Mary Ann Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York State Office of Mental Health
Original Assignee
New York State Office of Mental Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23462994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69636934(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by New York State Office of Mental Health filed Critical New York State Office of Mental Health
Application granted granted Critical
Publication of DE69636934D1 publication Critical patent/DE69636934D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69636934T 1995-01-11 1996-01-11 Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen Expired - Lifetime DE69636934D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/371,211 US5670539A (en) 1993-07-21 1995-01-11 Treatment of movement disorders using large neutral amino acids
PCT/US1996/000017 WO1996021437A1 (en) 1995-01-11 1996-01-11 Treatment of movement disorders using large neutral amino acids

Publications (1)

Publication Number Publication Date
DE69636934D1 true DE69636934D1 (de) 2007-04-12

Family

ID=23462994

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636934T Expired - Lifetime DE69636934D1 (de) 1995-01-11 1996-01-11 Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen

Country Status (6)

Country Link
US (2) US5670539A (de)
EP (1) EP0799034B1 (de)
AT (1) ATE355057T1 (de)
CA (1) CA2210233A1 (de)
DE (1) DE69636934D1 (de)
WO (1) WO1996021437A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200758B1 (en) 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
RU2151596C1 (ru) * 1999-03-10 2000-06-27 Казанский государственный университет им. В.И. Ульянова-Ленина Композиция аминокислот с микроэлементами и кальцием, обладающая противоопухолевой, антидепрессивной и противоаритмической активностью
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6620850B2 (en) * 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
CA2490308A1 (en) * 2002-07-12 2004-01-22 University Of Rochester Use of amino acids for treatment of various conditions
EP1528920B1 (de) * 2002-08-12 2013-07-24 Yuuichi Murayama Hemmung der abnormalen Prionproteinsproliferation mit Leucine, Isoleucine oder Valine
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
JP4651078B2 (ja) * 2003-03-10 2011-03-16 雅美 森山 異常プリオン蛋白質の増殖の抑制方法
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
KR101417201B1 (ko) * 2008-01-02 2014-07-08 마린 바이오 씨오., 엘티디. 신경변성 질환을 치료하기 위한 조성물 및 방법
JP2016515138A (ja) * 2013-03-14 2016-05-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｇｐｒ１３９の生理的リガンド

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100293A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US4129652A (en) * 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) * 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4296119A (en) * 1978-04-24 1981-10-20 Massachusetts Institute Of Technology Process and composition for reducing blood pressure in animals
US4209531A (en) * 1978-09-13 1980-06-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4252822A (en) * 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4438144A (en) * 1980-07-31 1984-03-20 Blackburn George L Amino acid preparation and therapy for treatment of stress and injury
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US4837219A (en) * 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
US5028622A (en) * 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5006559A (en) * 1988-08-31 1991-04-09 Clintec Nutrition Co. Method of use of branched-chain amino acids infusions to influence appetite
US5206218A (en) * 1989-04-03 1993-04-27 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
US5017616A (en) * 1989-11-30 1991-05-21 Jeffrey Askanazi Method for improving ventilation during sleep and treating sleep related ventilation abnormalities
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5393784A (en) * 1993-07-21 1995-02-28 New York State Office Of Mental Health Treatment of tardive dyskinesia with leucine, isoleucine, valine or mixtures thereof

Also Published As

Publication number Publication date
US5919823A (en) 1999-07-06
US5670539A (en) 1997-09-23
EP0799034A4 (de) 2002-05-22
EP0799034B1 (de) 2007-02-28
WO1996021437A1 (en) 1996-07-18
CA2210233A1 (en) 1996-07-18
ATE355057T1 (de) 2006-03-15
EP0799034A1 (de) 1997-10-08

Similar Documents

Publication Publication Date Title
DE69636934D1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
HUT74004A (en) Inhibitors of beta-amyloid protein production
GB2364059A (en) Beta-Secretase enzyme compositions and methods
ATE407573T1 (de) Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
MY121036A (en) Piperazinyl-heterocyclic compounds in the treatment of dementia.
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DE69434211D1 (de) Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen
SI0801564T1 (en) Use of nebivolol as an anti-atherogenic
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
IL129178A0 (en) Induction of nerve generation
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
DE69820053D1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE251912T1 (de) Verwendung des erythropoietins zur behandlung von rheumatoider arthritis
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
ATE209005T1 (de) Verwendung von threonin zur behandlung der phenylketonurie
DE69915849D1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
IL126157A0 (en) Method for treating excessive aggression
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
NO961496L (no) Behandling av allergiske sykdommer med terfenadinkarboksylat
WO2000030669A3 (en) Use of plasma phospholipid transfer proteins in treating cardiovascular dieases
ATE188384T1 (de) Verwendung von kollagen zur behandlung von krankhaften gelenkprozessen

Legal Events

Date Code Title Description
8332 No legal effect for de